Karim Fizazi, MD, PhD, is a medical oncologist, Head of the Department of Cancer Medicine at the Institute Gustave Roussy (IGR), one of the world’s leading cancer-research institutes, located in Villejuif, France and a Professor in Oncology at the University of Paris. www.gustaveroussy.fr
Professor Fizazi gained his medical degree and completed a Fellowship in 1995 and 1997, respectively. In 2003, he gained a PhD in Molecular Oncology. He is now President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI), and is a member of the Urogenital Tumours Study Group (GETUG), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research (AACR).
He is also currently involved in many phase I-III clinical trials including the GETUG 12, GETUG 13 and TAK700 post-docetaxel trials, where he is the global/national coordinating investigator. In 2013, Professor Fizazi coordinated the the Peace-1 phase III clinical trial investigating into the role of abiraterone acetate, and the Peace-2 phase III clinical trial testing cabazitaxel and pelvic lymph node irradiation in patients who presented with high-risk localized prostate cancer treated with ADT-radiotherapy.
To date, Professor Fizazi has published over 200 peer-reviewed articles, and is an associate editor of Annals of Oncology and a consulting editor of European Urology.